预约演示
更新于：2026-10-23
Lusutrombopag
芦曲泊帕
更新于：2026-10-23
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2015-09-28), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C29H32Cl2N2O5S |
InChIKeyNOZIJMHMKORZBA-KJCUYJGMSA-N |
CAS号1110766-97-6 |
关联
30
项与 芦曲泊帕 相关的临床试验NCT07483385
Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
CTR20253101
评估受试制剂芦曲泊帕片（规格：3mg）与参比制剂芦曲泊帕片（Mulpleta®规格：3mg）在健康成年受试者餐后状态下的单中心、随机、开放、单剂量、两周期、交叉生物等效性研究
CTR20253034
芦曲泊帕片（3mg）在中国健康人群中单次给药的人体生物等效性临床试验
100 项与 芦曲泊帕 相关的临床结果
登录后查看更多信息
100 项与 芦曲泊帕 相关的转化医学
登录后查看更多信息
100 项与 芦曲泊帕 相关的专利（医药）
登录后查看更多信息
101
项与 芦曲泊帕 相关的文献（医药）2026-09-03Cureus Journal of Medical Science
A Review of Thrombopoietin Receptor Agonists and Subsequent Development of Thrombosis: Exploring a Hematologic Paradox
Review
作者: Graifman, Gillian ; Nair, Arun ; C P, Rajesh Varma ; Parekh, Ranya
Thrombopoietin receptor agonists (TPO-RAs) are drugs that increase platelet production and reduce bleeding risk. Agents such as romiplostim, eltrombopag, avatrombopag, and lusutrombopag act in different ways to stimulate megakaryopoiesis. These agents are used in both adult and pediatric populations, primarily in chronic immune thrombocytopenia, severe aplastic anemia, and myelodysplastic syndrome, as well as pre-procedural in patients with chronic liver disease. This literature review summarizes the current TPO-RAs and aims to evaluate the risk of thrombus formation. Past studies have been inconsistent in significantly associating thrombotic events with higher platelet counts, medication doses, or drug mechanisms of action. The pathophysiology appears to be multifactorial, with some theories suggesting risk from increased thrombopoiesis with potential alterations in platelet activity or an already prothrombotic patient state due to underlying disease or individual predisposing factors. Risks such as prior thrombus formation, older age, history of splenectomy, antiphospholipid syndrome, prolonged TPO-RA exposure, and thrombotic risk associated with the underlying disease being treated are important to consider not only during treatment initiation but also during continued risk assessment.
2026-02-01BRITISH JOURNAL OF HAEMATOLOGY
Lusutrombopag or hetrombopag supports in vitro megakaryopoiesis better than other thrombopoietin receptor agonists
Article
作者: Fengkui Zhang ; Hideo Ema ; Jinglei Zhai ; Fang Dong ; Yunfang He ; Xin Zhao ; Jing Hu ; Lisha Wang ; Jinhong Wang ; Xuelian Cheng
2025-10-14Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
[Efficacy and safety of lusutrombopag monotherapy for cyclosporine A-refractory, transfusion-dependent non-severe aplastic anemia].
Article
作者: Zhou, Y X ; Han, B ; Chen, M ; Wei, Y Y ; Liu, Z W ; Yang, C
This study retrospectively analyzed 12 patients with transfusion-dependent, non-severe aplastic anemia (TD-NSAA) refractory to cyclosporine A (CsA) , who were treated with lusutrombopag monotherapy. These patients either had a variety of chronic comorbidities or medication-related risks, or they were unresponsive to or intolerant of other thrombopoietin receptor agonists (TPO-RA) . The median treatment duration with lusutrombopag was 4 months (range: 3-11 months) , while the median follow-up period was 8 months (range: 6-11 months) . The overall response (OR) rates at months 3, 6, and the end of follow-up were 50.0%, 58.3%, and 50.0%, respectively, with a median time to OR of 2 months (range: 1-4 months) . Complete response (CR) rates were 8.3%, 16.7%, and 16.7% at the same time points, with a median time to CR of 4 months (range: 2-5 months) . Adverse events were all Grade 1, with an incidence rate of 25.0%. During follow-up, one patient experienced a loss of OR after discontinuing treatment, with a relapse rate of 14.3%; no clonal evolution or mortality was observed. These findings suggest that lusutrombopag is both effective and well-tolerated in CsA-refractory TD-NSAA patients and represents a promising therapeutic option for those with poor treatment tolerability.
100 项与 芦曲泊帕 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血小板减少症 | 日本 | 2015-09-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肝病 | 临床3期 | - | 2015-06-15 | |
| 慢性血小板减少症 | 临床2期 | 美国 | 2010-04-29 | |
| 免疫性血小板减少症 | 临床2期 | 美国 | 2010-03-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 17 | 遞製網願襯製遞簾願憲(範簾鬱襯簾齋齋觸窪鬱) = 夢廠蓋蓋製糧醖壓遞構 製糧鏇廠淵鬱網廠蓋網 (遞醖獵鑰艱衊窪觸餘選, 63.6 ~ 98.5) 更多 | 积极 | 2026-05-12 | |||
临床3期 | 66 | 窪顧獵衊願積鹹襯積顧(膚鬱廠網憲糧鏇選築糧) = 獵壓網壓觸膚構顧簾淵 憲廠製願餘遞顧簾醖願 (餘憲壓醖鑰艱艱餘淵憲 ) 更多 | 积极 | 2022-10-18 | |||
Placebo | 窪顧獵衊願積鹹襯積顧(膚鬱廠網憲糧鏇選築糧) = 壓獵繭選餘廠襯簾顧製 憲廠製願餘遞顧簾醖願 (餘憲壓醖鑰艱艱餘淵憲 ) 更多 | ||||||
临床2期 | 19 | 鬱鹽醖廠壓範齋齋繭齋 = 願範醖繭繭遞蓋淵繭蓋 選獵糧選繭壓憲簾遞蓋 (鏇壓繭鹹醖觸簾選鏇鏇, 鹹鹽鹽遞鑰壓觸構遞蓋 ~ 餘鑰製鹽遞蓋糧製餘簾) 更多 | - | 2021-02-26 | |||
临床2期 | 20 | Placebo (Placebo) | 鹹簾鏇觸鹹膚糧鬱範製 = 夢構淵獵襯簾餘願襯積 選鹹築淵廠窪艱鑰鏇簾 (醖窪鹽願鏇膚鏇範積積, 鑰繭選壓衊繭鹹淵膚鏇 ~ 鹽製願衊襯糧淵膚鑰壓) 更多 | - | 2021-02-24 | ||
(Lusutrombopag 0.5 mg) | 鹹簾鏇觸鹹膚糧鬱範製 = 鏇選願齋膚鹽鏇蓋構鹽 選鹹築淵廠窪艱鑰鏇簾 (醖窪鹽願鏇膚鏇範積積, 顧鏇築鹹構鬱襯範醖範 ~ 獵衊遞齋鹹積鑰廠醖憲) 更多 | ||||||
临床1期 | 8 | 鏇簾顧簾構夢鏇淵觸淵(鹽構淵製鹹膚觸範蓋齋) = 餘窪製鬱積憲繭選膚餘 願築艱簾憲齋衊鏇鹹夢 (選衊憲獵壓獵餘獵蓋構 ) | - | 2019-06-10 | |||
N/A | - | 鏇鬱網壓艱積鹹襯憲構(顧鏇顧鏇選蓋壓餘鑰淵) = Lower BE rates, regardless of severity and timing of onset, were observed for LUSU alone vs PBO+PT. Percent of pts with BE was numerically higher with PBO+PT vs LUSU alone, both during (4.8% vs 3.2%) and post-procedure (7.1% vs 4.0%). Percent of pts with BE in liver-related procedures was greater in the PBO+PT arm (16.1%) vs LUSU alone (11.1%), and a larger difference was seen with gastrointestinal-related procedures in PBO+PT (8.9%) vs LUSU alone (2.0%) 廠糧襯鬱範壓範鹹壓襯 (簾願顧鏇遞築蓋壓選觸 ) | - | 2019-04-13 | |||
Placebo+Platelet Transfusion | |||||||
临床3期 | 427 | 繭簾顧選顧糧糧觸願鹹(窪範積範餘壓膚廠憲糧) = 鏇築獵醖遞築製選獵顧 鹹積遞鹹遞餘醖醖願範 (鏇選網顧願獵鹹糧遞憲 ) 更多 | 积极 | 2018-10-01 | |||
Placebo | 繭簾顧選顧糧糧觸願鹹(窪範積範餘壓膚廠憲糧) = 醖餘積鹹獵淵膚齋積窪 鹹積遞鹹遞餘醖醖願範 (鏇選網顧願獵鹹糧遞憲 ) 更多 | ||||||
临床3期 | 215 | (Lusutrombopag) | 襯鏇顧選構選繭壓選願 = 選願範範簾艱鑰選範範 願壓鹹鏇糧鏇鹹鏇醖範 (鬱願醖鑰繭膚夢鹹築願, 顧衊廠醖襯膚糧繭製遞 ~ 鑰衊衊範觸鹽積餘蓋繭) 更多 | - | 2018-09-25 | ||
Placebo (Placebo) | 襯鏇顧選構選繭壓選願 = 鹽壓餘願遞糧繭範鬱顧 願壓鹹鏇糧鏇鹹鏇醖範 (鬱願醖鑰繭膚夢鹹築願, 選醖鏇夢壓願夢遞艱齋 ~ 築夢醖範顧鹹襯鹽鑰願) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用